Secondary analysis of a trial of mepolizumab with or without FESS in 58 patients with severe CRSwNP: middle ear effusion fell from 22.8% to 14% at 6 months (p = 0.07, non-significant); hearing thresholds did not change, but ear symptom scores improved.
Secondary analysisn = 58
Homøe et al. Effect of Mepolizumab on Middle Ear Disease and Hearing Outcomes in CRSwNP